Citi Maintains $21 Price Target on Korro Bio as KRRO-121 and KRRO-111 Advance
at www.tipranks.com (Fri, 6-Nov 9:08 AM)
Korro Bio’s Buy Rating Reaffirmed on Clinical Catalysts and Financial Flexibility; Price Target Unchanged at $15
at www.tipranks.com (Fri, 6-Nov 9:01 AM)
